13D·WATCH Activist + Insider Intelligence Live feed Blog About Pilot
SCHEDULE Filed 2025-01-13 Event 2025-01-08 SEC 0000902664-25-000190 →

Pentwater Capital Management LP Poseida Therapeutics, Inc.

Stake: Shares: CUSIP: 73730P108 Class: Common Stock, par value $0.0001 per share

Item 4 — Purpose of Transaction

Pursuant to the terms of the Pentwater Support Agreement, the Pentwater Funds tendered the shares of Common Stock beneficially owned by them in the Tender Offer. The Tender Offer expired as scheduled at one minute following 11:59 p.m., New York City time, on January 7, 2025. The shares of Common Stock held by the Pentwater Funds were accepted for payment on January 8, 2025. As a result, the Reporting Persons no longer own, beneficially or otherwise, any securities of the Issuer. In addition, on January 8, 2025, following consummation of the Tender Offer, Merger Sub merged with and into the Issuer, with the Issuer being the surviving corporation (the "Merger"). Accordingly, at the effective time of the Merger, the Pentwater Support Agreement terminated pursuant to its terms.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
1 13D/G filings on this issuer
0 other filings besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest
Not in latest FINRA snapshot

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →